Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M.

Oncol Lett. 2019 Jun;17(6):4891-4900. doi: 10.3892/ol.2019.10153. Epub 2019 Mar 15.

2.

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.

Krefting F, Basara N, Schütte W, Späth-Schwalbe E, Alt J, Thiel S, Kimmich M, Fischer JR, Kurz S, Griesinger F, Christoph DC.

Oncol Res Treat. 2019;42(5):243-255. doi: 10.1159/000499321. Epub 2019 Apr 17.

PMID:
30995666
3.

[Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment].

Reinmuth N, Bitzer M, Deschler-Baier B, Fischer JR, Kuon J, Leipe J, Rawluk J, Schulz C, Heußel CP, Schultheiß M.

Dtsch Med Wochenschr. 2019 Mar;144(5):346-353. doi: 10.1055/a-0739-8194. Epub 2019 Jan 30. German.

PMID:
30699440
4.

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.

Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A.

Int J Cancer. 2019 Aug 1;145(3):649-661. doi: 10.1002/ijc.32133. Epub 2019 Feb 19.

PMID:
30653256
5.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators.

Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.

PMID:
30383906
6.

ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M.

Med Oncol. 2018 Jun 15;35(7):106. doi: 10.1007/s12032-018-1169-5.

PMID:
29905882
7.

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.

Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M.

Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24.

8.

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC.

Clin Lung Cancer. 2016 May;17(3):232-236.e1. doi: 10.1016/j.cllc.2016.03.003. Epub 2016 Mar 17.

9.

A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.

Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stöhlmacher J, Fischer JR, Mazières J, Chouaid C, Wolf M, Vinolas N, Soldatenkova V, Ripoche V, Nguyen T, Visseren-Grul C.

Lung Cancer. 2015 Dec;90(3):397-404. doi: 10.1016/j.lungcan.2015.11.007. Epub 2015 Nov 7.

PMID:
26791798
10.

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators.

J Thorac Oncol. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.

11.

Corrigendum: Worldwide variations in artificial skyglow.

Kyba CC, Tong KP, Bennie J, Birriel I, Birriel JJ, Cool A, Danielsen A, Davies TW, den Outer PN, Edwards W, Ehlert R, Falchi F, Fischer J, Giacomelli A, Giubbilini F, Haaima M, Hesse C, Heygster G, Hölker F, Inger R, Jensen LJ, Kuechly HU, Kuehn J, Langill P, Lolkema DE, Nagy M, Nievas M, Ochi N, Popow E, Posch T, Puschnig J, Ruhtz T, Schmidt W, Schwarz R, Schwope A, Spoelstra H, Tekatch A, Trueblood M, Walker CE, Weber M, Welch DL, Zamorano J, Gaston KJ.

Sci Rep. 2015 Aug 5;5:12180. doi: 10.1038/srep12180. No abstract available.

12.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators.

Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.

13.

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.

Thomas M, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, Schenk M, Schröder M, Villalobos M, Reinmuth N, Penzel R, Schnabel P, Acker T, Reuss A, Wolf M; ABC-Lung Cancer Group.

Eur Respir J. 2015 Jul;46(1):219-29. doi: 10.1183/09031936.00229014. Epub 2015 Mar 18.

14.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators.

Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18.

15.

Worldwide variations in artificial skyglow.

Kyba CC, Tong KP, Bennie J, Birriel I, Birriel JJ, Cool A, Danielsen A, Davies TW, Outer PN, Edwards W, Ehlert R, Falchi F, Fischer J, Giacomelli A, Giubbilini F, Haaima M, Hesse C, Heygster G, Hölker F, Inger R, Jensen LJ, Kuechly HU, Kuehn J, Langill P, Lolkema DE, Nagy M, Nievas M, Ochi N, Popow E, Posch T, Puschnig J, Ruhtz T, Schmidt W, Schwarz R, Schwope A, Spoelstra H, Tekatch A, Trueblood M, Walker CE, Weber M, Welch DL, Zamorano J, Gaston KJ.

Sci Rep. 2015 Feb 12;5:8409. doi: 10.1038/srep08409. Erratum in: Sci Rep. 2015;5:12180.

16.

Unexpected lymph node disease in resections for pulmonary metastases.

Seebacher G, Decker S, Fischer JR, Held M, Schäfers HJ, Graeter TP.

Ann Thorac Surg. 2015 Jan;99(1):231-6. doi: 10.1016/j.athoracsur.2014.08.038. Epub 2014 Nov 20.

PMID:
25440271
17.

Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.

Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium.

Oncologist. 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17.

18.

Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer.

Kreuter M, Vansteenkiste J, Herth FJ, Fischer JR, Eberhardt W, Zuna I, Reinmuth N, Griesinger F, Thomas M; TREAT investigators.

Respiration. 2014;87(3):204-10. doi: 10.1159/000355361. Epub 2013 Oct 30.

19.

Temperature stability of the sky quality meter.

Schnitt S, Ruhtz T, Fischer J, Hölker F, Kyba CC.

Sensors (Basel). 2013 Sep 11;13(9):12166-74. doi: 10.3390/s130912166.

20.

Changes in sensory properties and consumer acceptance of reduced fat pork Lyon-style and liver sausages containing inulin and citrus fiber as fat replacers.

Tomaschunas M, Zörb R, Fischer J, Köhn E, Hinrichs J, Busch-Stockfisch M.

Meat Sci. 2013 Nov;95(3):629-40. doi: 10.1016/j.meatsci.2013.06.002. Epub 2013 Jun 10.

PMID:
23811098

Supplemental Content

Loading ...
Support Center